GlassScriptPhysician profile
Raisa Pustylnikov
NPI 1700849494
$4,970.03
in general payments reported to CMS, 2019-2025
19 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $508 · 2021: $873 · 2022: $1,183 · 2023: $700 · 2024: $448 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,089.79 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,221.42 | 2023-2025 | Caplyta |
| Alkermes, INC. | $240.73 | 2022-2023 | Lybalvi |
| Nestle Healthcare Nutrition INC. | $173.53 | 2021-2023 | |
| Abbvie INC. | $171.02 | 2019-2022 | |
| Horizon Therapeutics Plc | $163.25 | 2020-2022 | |
| Allergan, INC. | $145.87 | 2019 | |
| Amarin Pharma, INC. | $129.43 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $124.92 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.26 | 2021-2023 | Xifaxan |
| Pfizer INC. | $118.54 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $95.84 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $46.21 | 2020 | |
| Celgene Corporation | $26.72 | 2019 | |
| Amgen INC. | $26.44 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.14 | 2021 | |
| Incyte Corporation | $19.17 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raisa Pustylnikov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.